Cyclophilin inhibitor 1 is an effective and orally bioavailable cyclophilin A inhibitor with a Kd of 5 nM, showing potent anti-HCV activity, and an EC50 for HCV 2a of 98 nM.

CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).

CypD-IN-3, a potent and subtype-selective cyclophilin D (CypD) inhibitor, exhibits a high affinity for CypD with an IC50 value of 0.01 μM. It is applicable in the research of various conditions, such as oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes [1].

CypD-IN-4 is a potent, subtype-selective cyclophilin D (CypD) inhibitor exhibiting a high affinity for CypD with an IC50 value of 0.057 μM. This compound is utilized in the research of various diseases, such as oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes [1].

RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μμ-15 μμ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity[1]. RAS/RAS-RAF-IN-1 (compound 89; for 4 hours) has an EC50 of 0.5 μμ-5.0 μμ for BRAF-GTP-KRAS-G12C disruption and has an IC50 of 1.0 μμ-10 μμ for pERK inhibition in H358 cells[1]. [1]. Meizhong Jin, et al. Compounds that participate in cooperative binding and uses thereof. WO2020132597A1.

CypD-IN-1, a potent and subtype-selective inhibitor targeting cyclophilin E (CypE), demonstrates high affinity with IC50 and Ki values of 0.013 μM and 0.072 μM, respectively. This compound is valuable for research into various conditions, including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes [1].